Mark T. Sadaka Appointed as Co-lead Counsel in Zostavax National Product Liability Lawsuits

Monday, November 12, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Sadaka Associates founder Mark T. Sadaka was appointed as co-lead counsel of the Zostavax Multi District Litigation (MDL).

ENGLEWOOD, N.J., Nov. 12, 2018 /PRNewswire-PRWeb/ -- Mark T. Sadaka was appointed by Judge Harvey

Bartle of the Eastern District of Pennsylvania as co-lead counsel of the Zostavax Multi District Litigation (MDL). As co-lead counsel, Mr. Sadaka will help lead a team of attorneys who are highly skilled at litigating these complex cases.

The Zostavax Multi-District Litigation (MDL) will ultimately consist of thousands of lawsuits alleging that Merck's Zostavax vaccine resulted in significant injuries for thousands of people including blindness, stroke, and heart attacks. Merck requested that all the cases be heard in front of one court for pre-trial proceedings due to the large number of injury cases.

Mark T. Sadaka has been investigating severe Zostavax injury claims for over seven years and has numerous cases currently pending all over the country. Mr. Sadaka has participated in dozens of depositions and reviewed millions of pages of Merck documents, providing him the foundation for this entire litigation. Sadaka Associates, LLC is currently filing claims alleging that Zostavax caused injuries such as, Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), brain inflammation (encephalitis), stroke, vasculitis, blindness, eye infections, retinal damage, and acute retinal necrosis.

Mr. Sadaka has also spoken on the Zostavax litigation to other counsel at numerous conferences around the county. He co-petitioned for the creation of a Zostavax litigation group for the American Association of Justice. He was appointed co-chair of that group, which has the sole purpose of fostering cooperation amongst plaintiffs' counsel.

About Zostavax Vaccine

Zostavax is a live virus vaccine made by pharmaceutical giant Merck, and approved by the U.S. Food and Drug Administration in 2006. It was the only approved shingles vaccine in the United States until late 2017, which allowed the company to earn a reported $749 million in sales.

Zostavax is designed to reduce the risk of getting herpes zoster — a painful and debilitating condition commonly known as "shingles" — in individuals ages 50 years and older, who are at increased risk of developing the virus. The vaccine is typically recommended for people aged 60 years and older by the U.S. Centers for Disease Control and Prevention, and doctors commonly give the vaccine in a one-dose shot. Zostavax contains a live, but weakened form of the herpes zoster virus.

About Mark T. Sadaka and Sadaka Associates, LLC

Mark T. Sadaka is the principal of Sadaka Associates, LLC, in Englewood, New Jersey with offices in New York and Maryland. He is an accomplished trial lawyer with a specialized medical background that has made him leader and invaluable resource in the realm of medically complicated cases. Mr. Sadaka represents people hurt by defective drugs, medical devices, vaccines, exposure to hazardous chemicals, and other dangerous products. He also represents victims of corporate fraud.

He has successfully prosecuted a number of first-of-its-kind pharmaceutical related lawsuits, including brain damage caused by Zostavax and aggressive prostate cancer caused by Avodart. Through nine years of persistence and innovation, Mr. Sadaka was the first ever to successfully prove that the Gardasil vaccine killed a 21-year old woman in Tarsell v. DHHS, 10-cv-251 (US Court of Federal Claims). Sadaka Associates has represented or currently represents clients in litigation involving transvaginal mesh, hernia mesh, diabetes drugs, anti-psychotics, oral contraceptives, spinal cord stimulators, and vaccines.

 

SOURCE Sadaka Associates



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store